|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2013
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XC25
|
|
gptkbp:brand
|
gptkb:Gazyva
gptkb:Gazyvaro
|
|
gptkbp:CASNumber
|
940078-46-4
|
|
gptkbp:combines
|
gptkb:bendamustine
gptkb:chlorambucil
chemotherapy
|
|
gptkbp:contraindication
|
hypersensitivity to obinutuzumab
|
|
gptkbp:developedBy
|
gptkb:Genentech
gptkb:Roche
|
|
gptkbp:drugClass
|
antineoplastic agent
|
|
gptkbp:halfLife
|
28 days (approximate)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
obinutuzumab
|
|
gptkbp:immunogenicity
|
low
|
|
gptkbp:indication
|
first-line treatment of CLL
relapsed/refractory follicular lymphoma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:CD20_antigen
|
|
gptkbp:mechanismOfAction
|
induces antibody-dependent cellular cytotoxicity
induces complement-dependent cytotoxicity
induces direct cell death
|
|
gptkbp:origin
|
recombinant DNA technology
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:riskFactor
|
gptkb:progressive_multifocal_leukoencephalopathy
gptkb:tumor_lysis_syndrome
hepatitis B reactivation
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
cough
infections
neutropenia
thrombocytopenia
infusion reactions
pyrexia
musculoskeletal pain
|
|
gptkbp:target
|
gptkb:CD20
|
|
gptkbp:type
|
humanized monoclonal antibody
|
|
gptkbp:UNII
|
6X9OC3H4II
|
|
gptkbp:usedFor
|
gptkb:small_lymphocytic_lymphoma
chronic lymphocytic leukemia
follicular lymphoma
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
no
|
|
gptkbp:bfsParent
|
gptkb:CD20
gptkb:B_cell
gptkb:Gazyva
|
|
gptkbp:bfsLayer
|
7
|